Tirzepatide in Adolescents With Obesity
JAMA 10.1001/jama.2026.23420November 15, 2026 at 6:00 PM EST
In adolescents with obesity or overweight with obesity-related complications, tirzepatide, in addition to healthy lifestyle intervention, led to significant reductions in percent change in BMI compared with placebo at 72 weeks.
Meeting Information: This paper will be presented at ObesityWeek 2026 in Washington, DC.
Check out the JAMA Network ObesityWeek 2026 collection
JAMA Network is publishing two clinical trials and its fourth JAMA Summit Report at ObesityWeek.
Sunday, November 15
Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity (JAMA Original Investigation; meeting presentation)
Tirzepatide in Adolescents With Obesity (JAMA Original Investigation; meeting presentation; see related commentary)
Tale of Two Estimands (JAMA Editor's Note)
Monday, November 16
Glucagon-Like Peptide-1 Utilization Following Withdrawal of Medicaid Coverage for Weight Loss (JAMA Research Letter; timed to coincide with meeting)
Tuesday, November 17
Toward a Healthier Future Through Obesity Prevention and Care (JAMA Special Communication; meeting presentation)
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Need more information? Contact us.